Andreas Parkner

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function

Denise Wolleschak, Thomas Sebastian Mack, Florian Perner, Stephanie Frey et autres

The vast majority of acute myeloid leukemia (AML) patients harboring an FLT3-ITD mutation experience relapse within a short period of time after discontinuation of chemotherapy.[1][1] Treatment options include experimental trials using FLT3-tyrosine kinase inhibitors (TKI) or allogeneic stem cell

de (code pays fourni par la source)

A Novel ABO Gene Variant Leads to Discrepant Results in Forward/Reverse and Molecular Blood Grouping

Meike Goebel, Ines Halm-Heinrich, Andreas Parkner, Gabriele Rink et autres

BACKGROUND: Discrepant results in antigen and reverse ABO blood typing are often caused by a variant ABO gene. Molecular analysis can help to characterize such variants. Here, we describe the identification of a novel ABO gene variant in a patient with aberrant …

de, us (code pays fourni par la source)

Contents of Forthcoming Issues

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Contents Vol. 40, 2013

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Vol. 40, Issue 6, December 2013

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Imprint

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

News

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Editorial Board

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Acknowledgement to Reviewers

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Meetings and Conferences

Jasmin Kemptner, Karin Witzeneder, Simone Hennerbichler, Christian Gabriel et autres

Detection of a new HLA‐B*15 allele, HLA‐B*15:238, in a voluntary stem cell donor

Andreas Parkner, Ines Halm-Heinrich, J. Hahn, M.U. Heim

The newly detected HLA-B*15:238 is distinguished from HLA-B*15:52 by a single-nucleotide exchange at position 527 where T is replaced by A.

de (code pays fourni par la source)

Identification of a novel HLA‐DRB1*15 allele, DRB1*1533, in a recently registered stem cell donor

Andreas Parkner, Mira Mosebach, Ines Halm-Heinrich, M.U. Heim

The new human leukocyte antigen (HLA)-DRB1 nucleotide sequence differs from HLA-DRB1*150101 in position 130 with an A instead of a T resulting in an amino acid change from Cysteine to Serine.

de (code pays fourni par la source)